Literature DB >> 12953816

Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.

Mitsuharu Inami, Koiti Inokuchi, Kazutaka Nakayama, Hideto Tamura, Takashi Shimada, Kazuo Dan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12953816     DOI： 10.1007/BF02983390

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  6 in total

1.  p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia.

Authors:  J Abo; K Inokuchi; K Dan; T Nomura
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

2.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

3.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

Authors:  Wolf-K Hofmann; Letetia C Jones; Nathan A Lemp; Sven de Vos; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann; H Phillip Koeffler
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

4.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

Authors:  Nikolas von Bubnoff; Folker Schneller; Christian Peschel; Justus Duyster
Journal:  Lancet       Date:  2002-02-09       Impact factor: 79.321

5.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Andrew Grigg; Chris Arthur; Kerry Taylor; Richard Herrmann; Kevin P Lynch; Timothy P Hughes
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

6.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Authors:  A Hochhaus; S Kreil; A S Corbin; P La Rosée; M C Müller; T Lahaye; B Hanfstein; C Schoch; N C P Cross; U Berger; H Gschaidmeier; B J Druker; R Hehlmann
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528
  6 in total
  2 in total

1.  RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.

Authors:  Koiti Inokuchi; Satoshi Wakita; Tsuneaki Hirakawa; Hayato Tamai; Norio Yokose; Hiroki Yamaguchi; Kazuo Dan
Journal:  Int J Hematol       Date:  2011-08-24       Impact factor: 2.490

2.  Aleukemic leukemia cutis in a patient with Philadelphia chromosome-positive biphenotypic leukemia.

Authors:  Masahiro Onozawa; Satoshi Hashino; Hiroe Kanamori; Koh Izumiyama; Masakatsu Yonezumi; Koji Chiba; Takeshi Kondo; Takashi Fukuhara; Junji Tanaka; Masahiro Imamura; Masahiro Asaka
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.